Related Experiment Video
Updated: Aug 17, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Will the dark sky over advanced renal cell carcinoma soon become brighter?
1Clinic of Medical Oncology, Institut Jules Bordet, Bd de Waterloo 125, Brussels 1000, Belgium.
Abstract:
Until recently, immunotherapy has been the most efficient treatment for advanced renal cell carcinoma, but clinical results are largely unsatisfactory. More promising agents are being developed as a result of an improved understanding of the biology of the disease. Several agents that target known biological abnormalities of the disease are now being tested in the clinic. This review describes the encouraging clinical results obtained to date with these new drugs or combinations of drugs.
Insights
New targeted therapies show promise for advanced renal cell carcinoma, offering better outcomes than traditional immunotherapy. Research is exploring novel agents based on improved disease biology understanding.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Advanced renal cell carcinoma (RCC) treatment has relied on immunotherapy, but with limited success.
- A deeper understanding of RCC biology is driving the development of new therapeutic strategies.
- Current treatments often fail to provide satisfactory clinical outcomes for patients with advanced disease.
Purpose of the Study:
- To review the latest clinical findings on novel therapeutic agents for advanced renal cell carcinoma.
- To highlight drugs and drug combinations targeting specific biological pathways in RCC.
- To assess the efficacy and potential of emerging treatments in the context of current therapeutic limitations.
Main Methods:
- Review of recent clinical trial data and published literature.
- Analysis of therapeutic agents targeting known molecular abnormalities in renal cell carcinoma.
- Synthesis of information on drug combinations and monotherapies in advanced RCC.
Main Results:
- Several novel agents and combination therapies are demonstrating encouraging clinical activity.
- Emerging treatments show potential to improve upon the efficacy of traditional immunotherapy for advanced RCC.
- Early clinical results suggest these targeted approaches may overcome current treatment challenges.
Conclusions:
- New targeted therapies represent a significant advancement in the treatment of advanced renal cell carcinoma.
- Improved understanding of RCC biology is yielding more effective treatment options.
- Further clinical investigation of these promising agents is warranted to optimize patient outcomes.
